Company Overview
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -94.51% |
| 6 Months: | -20.00% |
| 3 Months: | -7.83% |
| 1 Month: | +36.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 96.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GRI GRI Bio, Inc. PHARMA | 2.00 | -0.71 | $4.37M | 0.00% | - | -142.02% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 100.00K | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.16M | -1.14M | -1.03M | -2.60M | -2.31M | -1.25M | -2.63M | -189.00K | -186.00K | -988.00K | -5.93M | -2.44M | -1.90M | -2.26M | -2.13M | -3.05M | -2.90M | -3.37M | -2.00M |
| Net Income | -1.16M | -1.15M | -1.04M | -2.64M | -2.31M | -1.26M | -302.00K | -295.00K | -351.00K | -2.15M | -6.75M | -2.14M | -1.89M | -2.25M | -2.12M | -3.05M | -2.89M | -3.36M | -2.00M |
| Diluted EPS | - | -0.25 | -0.23 | -0.46 | -0.34 | -0.18 | -11.62 | -0.35 | -0.39 | -15.04 | -239.37 | -65.78 | -101.05 | -61.85 | -11.42 | -162.30 | -1.31 | -1.28 | -1.61 |
| R&D Expense | 883.00K | 808.00K | 733.00K | 1.77M | 1.20M | 215.00K | 1.27M | 59.00K | 63.00K | 116.00K | 880.00K | 1.19M | 933.00K | 877.00K | 1.12M | 1.64M | 1.88M | 1.77M | 361.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 100.00K | 0 | - | - | - | - |
| Operating Income | -4.79M | -9.26M | -2.24M | -11.39M | -8.23M | -11.98M |
| Net Income | -4.82M | -9.30M | -3.22M | -13.04M | -8.21M | -11.96M |
| Diluted EPS | -1.07 | -1.42 | -24.95 | -5,018.09 | -1,545.55 | -121.80 |
| R&D Expense | 3.71M | 5.19M | 242.00K | 3.23M | 3.77M | 6.82M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 955.00K | 8.34M | 383.00K | 2.96M | 5.74M | 8.67M |
| Total Equity | 3.21M | -1.45M | -4.85M | -1.62M | 259.00K | 4.03M | 6.01M |
| Cash & Equivalents | - | 109.00K | 3.70M | 9.00K | 1.81M | 5.03M | 8.23M |
| Total Liabilities | - | 2.41M | 2.52M | 2.01M | 2.70M | 1.71M | 2.66M |
| Current Liabilities | - | 2.23M | 2.44M | 1.99M | 2.70M | 1.64M | 2.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.71M | -8.31M | -1.08M | -8.99M | -8.61M | -10.19M |
| Investing Cash Flow | -2.00K | -3.84M | -3.00K | -8.00K | 0 | -3.00K |
| Financing Cash Flow | -4.00K | 15.75M | 1.01M | 10.80M | 11.83M | 13.39M |
| Capital Expenditure | -2.00K | -0 | -3.00K | -8.00K | -0 | -3.00K |
| Free Cash Flow | -3.71M | -8.31M | -1.09M | -9.00M | -8.61M | -10.19M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -4,788.0% | - | - | - | - | - |
| Net Margin % | -4,822.0% | - | - | - | - | - |
| ROE % | 331.6% | 191.9% | 198.0% | -5,033.6% | -203.5% | -199.0% |
| ROCE % | 377.0% | -157.2% | 139.0% | -4,396.5% | -200.7% | -198.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 1.32% | 28.78K | $55.55K |
| 2 | Vanguard Capital Management LLC | 0.98% | 21.37K | $41.24K |
| 3 | Geode Capital Management, LLC | 0.63% | 13.87K | $26.77K |
| 4 | Citadel Advisors Llc | 0.61% | 13.38K | $25.82K |
| 5 | Morgan Stanley | 0.40% | 8.74K | $16.86K |
| 6 | UBS Group AG | 0.23% | 4.92K | $9.49K |
| 7 | Tower Research Capital LLC (TRC) | 0.11% | 2.43K | $4.70K |
| 8 | Blackrock Inc. | - | 7 | $13 |
| 9 | Danske Bank A/s | - | 2 | $3 |
| 10 | Barclays Plc | - | 83 | $160 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GRI
Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQMFdrejZORmR2c0FkbDhMMUg1UlRaOG5fR2d3Nm1NREpzQ2hEWFFTNGI0d2xtMHZuNWdEbExQc0FIY0VEOHpwNGpSZThjRThtOGZia0YwQl9VZGVmNmdBUFUxbjdDVXVDSkFrMjhWVEE4T1I2TXNYM3pxR3REUjdaYlo3c0otR25kU2x0N1…
GRI Bio Reports Phase 2a Data Showing Repair Phenotype and FVC Improvement with GRI-0621 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQdzI2RnRqcUxhdFAtclRyMV9sbmE5UTJIZ3R4OFNmSTJXekJiaHlTVzZJd0RpSnlKZVotTV9kNW5VTGJqSERTeHFBVlpkNGdickwxNmZuQWNfUzhUSTYwQnF3OVFmX1hSUy15VU1JVk1qLTZEZDdienJ4dTlRMW1rLU5OTnBDTzA5TkYtc3…
GRI Bio Surges As Phase 2a IPF Drug Data Nears - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1ocmFSSzlRcERZVWdfZUF0eW1VR25lREhzVkhEejluUnBHV21rY2JmTllSYmRDbV9WZmM0aVNScF9SbjhDSElzZEM1TjhUUENhby10UVltRmh6RFQxeUZ0S2czTW5uSG1DSDJrT2dn?oc=5" target="_blank">GRI Bio Surges As P…
Gri Bio reports Phase 2a data for IPF drug candidate GRI-0621 - Investing.com UK
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQRDYzSFVLRGxBcG0wSUxkX254RVVuYkdlRzVGZ2M5QVUyVEdJcUtVRVdoUHJhd1NER1JNUUhTR25BcWs3M25XSDNpWEdjaVBVdU1ZcC1wNzIwcmRPRE5XZ3ZneVdLSHVpMXBrNTZsTk5pZ2k3VENEc1liMFBQLThuN3h3MlJKOVdwSll1a3…
GRI Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFAwMVRHZ1JZRlZwa0t1bmNpbExCM1dOcTBKWFVjM1FTWnpZR1ZvSUhQUEI5S2dvOFhXQ2JBb0FidjFEQ0hlWUVjSFBsN01laXY2Y1UxTnQ5bE1INEhIaGhDVXpDRGtxMUFUNmxFMTJxWGQ4OWJHMnZjUA?oc=5" target="_blank">GRI F…
GRI Bio Company Profile & Introduction - Moomoo
<a href="https://news.google.com/rss/articles/CBMijwNBVV95cUxQdXpaY25HcmZXVVhXckV1N1FOYVl5ekZZU0VhQjQtQk8wRnlQdjdMdkNobm02U1pZZFlsNHFhem1iRHdMZjNIT0VQdDlqRXZUWlNXMDJLVGRkLWJQU2tIVDZIb0VzV25TOGRUYjU2VGppN19jN0gwYmR0SGlUYjVwTWJwY3BJcEk1cERYcj…
GRI — Frequently Asked Questions
What is the current share price of GRI Bio, Inc. (GRI)?
As of 2026-09-19 21:16 PDT, GRI Bio, Inc. (GRI) trades at $2.00 on NasdaqCM. Its 52-week range is $1.38 to $63.28.
What is the market capitalisation of GRI?
GRI Bio, Inc. (GRI) has a market capitalisation of $4.37M on NasdaqCM.
What is the P/E ratio of GRI?
GRI trades at a trailing price-to-earnings (P/E) ratio of -0.71. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.41.
What is the return on equity (ROE) of GRI?
GRI has a return on equity (ROE) of -142.02%.
Is GRI a good stock to buy?
This page provides a data-driven analysis of GRI Bio, Inc. (GRI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.